Prevalence and predictors of blood-brain barrier damage in the HAART era. (Q42208551)

18 October 2017

title

Prevalence and predictors of blood-brain barrier damage in the HAART era. (English)

1 reference

18 October 2017

1 reference

A Calcagno

1

1 reference

18 October 2017

M C Alberione

2

1 reference

18 October 2017

A Romito

3

1 reference

18 October 2017

D Imperiale

4

1 reference

18 October 2017

V Ghisetti

5

1 reference

18 October 2017

S Audagnotto

6

1 reference

18 October 2017

F Lipani

7

1 reference

18 October 2017

S Raviolo

8

1 reference

18 October 2017

G Di Perri

9

1 reference

18 October 2017

S Bonora

10

1 reference

18 October 2017

publication date

28 June 2014

1 reference

18 October 2017

published in

Journal of NeuroVirology

1 reference

18 October 2017

volume

20

1 reference

18 October 2017

issue

5

1 reference

18 October 2017

page(s)

521-525

1 reference

https://scigraph.springernature.com/pub.10.1007/s13365-014-0266-2

18 October 2017

exact match

0 references

cites work

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Body fluid biomarkers in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Acquired immunodeficiency syndrome and the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

IgG production within the central nervous system: a critical review of proposed formulae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Multiple sclerosis: The blood-brain-barrier and the measurement of de novo central nervous system IgG synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

Oligoclonal IgG bands in Japanese multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0266-2

External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients

21 January 2018

1 reference

12 December 2020

Cerebrospinal fluid analysis in human immunodeficiency virus infection

1 reference

12 December 2020

Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease

1 reference

12 December 2020

CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel

1 reference

12 December 2020

CSF protein and cellular profiles in various stages of HIV infection related to neurological manifestations

1 reference

12 December 2020

Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment.

1 reference

12 December 2020

Quantitative cerebrospinal fluid IgG measurements as a marker of disease activity in multiple sclerosis

1 reference

12 December 2020

10.1007/S13365-014-0266-2

Identifiers

DOI

1 reference

18 October 2017

1 reference